CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease.
about
The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomasAntibody-based immunotherapy for ovarian cancer: where are we at?Challenges in Biomarker Discovery: Combining Expert Insights with Statistical Analysis of Complex Omics Data.Past, present and future targets for immunotherapy in ovarian cancerMolecular approaches to personalizing management of ovarian cancer.Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy.Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.Quantification of the concentration gradient of biomarkers between ovarian carcinoma interstitial fluid and blood.Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor MarkersPlasma miR-200b in ovarian carcinoma patients: distinct pattern of pre/post-treatment variation compared to CA-125 and potential for prediction of progression-free survivalNadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer.Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer.Clinically Meaningful Use of Blood Tumor Markers in Oncology.Personalized ovarian cancer disease surveillance and detection of candidate therapeutic drug target in circulating tumor DNA.NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.Reflection on the discovery of carcinoembryonic antigen, prostate-specific antigen, and cancer antigens CA125 and CA19-9.Prognostic and predictive value of CA-125 in the primary treatment of epithelial ovarian cancer: potentials and pitfalls.Carboxyl-terminal domain of MUC16 imparts tumorigenic and metastatic functions through nuclear translocation of JAK2 to pancreatic cancer cells.The role of biomarkers in the management of epithelial ovarian cancer.Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer.Serum endocan levels in endometrial and ovarian cancers.Does HE4 have a role as biomarker in the recurrence of ovarian cancer?
P2860
Q26992102-B9254A5B-6E19-497A-BDB2-5F1220AC967CQ27000514-4ECBFE58-0B96-4A40-A411-012856C51767Q34555631-7C5F9F5A-2E6B-42B6-A979-E13141EB4D03Q35034010-5DA7317C-0D01-4EEC-92DD-95186908F63AQ35760160-377E3AEF-0193-4A31-98DF-FD482CA2F6A7Q35830931-767396C9-AF21-418C-9286-9EDF8F4289BEQ35872796-A4E64B1E-96A5-4173-995A-FC5A16C59ED9Q35881722-216AEB66-E05B-4094-B41C-6BFA2E45DD4EQ36250701-30B4AF78-1661-4395-86E3-783259D1FA1BQ36372283-2C16A7FA-5FB1-4015-B4B7-E2A553F4122BQ36546798-BFE22795-0514-449E-B680-98FD152D0B18Q36816028-687F0EB7-865C-43D5-BFDF-5CF85777D28BQ37409836-80C5547F-9E52-4FA6-914A-2DDA2B51398AQ37500722-361679BB-F8D0-4B62-AB09-81552D7C3610Q37584308-103E5737-022C-4F27-A155-DB47F8836939Q37590339-0133A809-0DF8-4163-9737-50147D2E4531Q37698104-11117215-A42A-4AEA-80A2-C8E199D5021CQ37977414-C56A7421-41AE-4726-859D-B15882911775Q38908575-26C8BC8B-3920-4AC6-8782-530136094DFAQ39281140-613A5601-E23E-4DDD-94EA-BCA8CBBDD695Q44340325-AEFA34A3-7079-4EAD-AD1A-76E96D94070EQ47982714-365B335B-69AC-45ED-84F9-7141FC6BF47BQ50921075-BE06A083-0E19-48D7-9069-134AD3C4F14E
P2860
CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
CA 125 and the detection of re ...... arker for a difficult disease.
@ast
CA 125 and the detection of re ...... arker for a difficult disease.
@en
CA 125 and the detection of re ...... arker for a difficult disease.
@nl
type
label
CA 125 and the detection of re ...... arker for a difficult disease.
@ast
CA 125 and the detection of re ...... arker for a difficult disease.
@en
CA 125 and the detection of re ...... arker for a difficult disease.
@nl
prefLabel
CA 125 and the detection of re ...... arker for a difficult disease.
@ast
CA 125 and the detection of re ...... arker for a difficult disease.
@en
CA 125 and the detection of re ...... arker for a difficult disease.
@nl
P2860
P356
P1433
P1476
CA 125 and the detection of re ...... arker for a difficult disease.
@en
P2093
Robert C Bast
P2860
P304
P356
10.1002/CNCR.25203
P407
P577
2010-06-01T00:00:00Z